FN-1501

FN-1501 is a small molecule inhibitor that targets multiple kinases, most notably FMS-like tyrosine kinase 3 (FLT3), cyclin-dependent kinases CDK2, CDK4, and CDK6. It also inhibits other tyrosine kinases such as KIT, PDGFR, ALK, RET, and VEGFR2. By inhibiting these kinases—key regulators of cell cycle progression and survival—FN-1501 induces apoptosis and suppresses tumor cell proliferation in cancer cells overexpressing these targets. Preclinical studies have shown potent antiproliferative activity against acute myeloid leukemia (AML) models as well as solid tumors. The drug has been evaluated in phase I/II clinical trials for advanced solid tumors and relapsed/refractory AML but development appears to have been discontinued[1][5][7][9].

Other names

4-((7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)-n-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1h-pyrazole-3-carboxamide